Roger S Lo

List of Publications by Year in Descending Order

72 papers	20,276 citations	44 h-index	84 g-index
84 ext. papers	23,558 ext. citations	22 avg, IF	6.11 L-index

#	Paper	IF	Citations
72	Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. *Cell Reports Medicine*, **2021**, 2, 100426	18	7
71	Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. *Cell Reports Medicine*, **2021**, 2, 100411	18	1
70	SPRED1 deletion confers resistance to MAPK inhibition in melanoma. *Journal of Experimental Medicine*, **2021**, 218,	16.6	6
69	Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects. *PLoS ONE*, **2021**, 16, e0252597	3.7	0
68	Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity. *Cancer Discovery*, **2021**, 11, 714-735	24.4	11
67	Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. *Cancer Cell*, **2021**, 39, 1375-1387.e6	24.3	16
66	Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in overcoming targeted therapy dosage challenges.. *Cancer Discovery*, **2021**,	24.4	1
65	Trying for a BRAF Slam Dunk. *Cancer Discovery*, **2020**, 10, 640-642	24.4	0
64	Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. *Nature Medicine*, **2020**, 26, 781-791	50.5	29
63	Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. *Nature Medicine*, **2020**, 26, 1564-1568	50.5	27
62	Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). *Journal of Translational Medicine*, **2020**, 18, 346	8.5	2
61	Melanoma to Vitiligo: The Melanocyte in Biology & Medicine-Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting. *Journal of Investigative Dermatology*, **2020**, 140, 269-274	4.3	1
60	The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018 **2019**, 7, 221		2
59	The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. *Frontiers in Oncology*, **2018**, 8, 584	5.3	9
58	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. *Clinical Cancer Research*, **2018**, 24, 3366-3376	12.9	43
57	High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity. *Analytical Chemistry*, **2018**, 90, 3299-3306	7.8	22
56	Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. *Cancer Discovery*, **2018**, 8, 74-93	24.4	49

55	Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. *Cell Reports*, **2017**, 19, 1189-1201	10.6	749
54	Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. *Cancer Discovery*, **2017**, 7, 188-201	24.4	692
53	Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. *Cancer Discovery*, **2017**, 7, 1248-1265	24.4	90
52	Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. *Nature Cell Biology*, **2016**, 18, 1090-101	23.4	186
51	Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. *New England Journal of Medicine*, **2016**, 375, 819-29	59.2	1724
50	Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. *Nature Communications*, **2016**, 7, 12348	17.4	35
49	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. *Cell*, **2016**, 165, 35-44	56.2	1552
48	JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. *Cell Discovery*, **2016**, 2, 16028	22.3	42
47	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. *Nature*, **2016**, 532, 250-4	50.4	205
46	The state of melanoma: challenges and opportunities. *Pigment Cell and Melanoma Research*, **2016**, 29, 404-16	4.5	63
45	Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. *Cancer Cell*, **2015**, 27, 240-56	24.3	226
44	Therapy-induced tumour secretomes promote resistance and tumour progression. *Nature*, **2015**, 520, 368-72	50.4	317
43	Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. *Cell*, **2015**, 162, 1271-85	56.2	377
42	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 10995-1000	11.5	112
41	Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. *Journal of Translational Medicine*, **2015**, 13, 210	8.5	72
40	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. *European Journal of Cancer*, **2015**, 51, 2792-9	7.5	202
39	Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma. *Methods in Molecular Biology*, **2014**, 1102, 163-74	1.4	12
38	Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. *Cancer Discovery*, **2014**, 4, 80-93	24.4	700

37	Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. *Cancer Discovery*, **2014**, 4, 423-33	24.4	180
36	Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. *Molecular Cancer*, **2014**, 13, 194	42.1	72
35	COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. *Molecular Oncology*, **2014**, 8, 250-60	7.9	32
34	Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. *Nature Communications*, **2014**, 5, 3901	17.4	59
33	Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. *Nature Communications*, **2014**, 5, 5712	17.4	374
32	A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. *Cancer Discovery*, **2014**, 4, 69-79	24.4	118
31	Melanoma prognostics and personalized therapeutics at a crossroad. *Journal of Investigative Dermatology*, **2013**, 133, 292-5	4.3	1
30	Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. *Angewandte Chemie - International Edition*, **2013**, 52, 3379-83	16.4	175
29	Innenr□ktitelbild: Polymer Nanofiber-Embedded Microchips for Detection, Isolation, and Molecular Analysis of Single Circulating Melanoma Cells (Angew. Chem. 12/2013). *Angewandte Chemie*, **2013**, 125, 3619-3619	3.6	
28	Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma. *Journal of Investigative Dermatology*, **2013**, 133, 274-6	4.3	12
27	Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. *Journal of Clinical Oncology*, **2013**, 31, 1767-74	2.2	295
26	Polymer Nanofiber-Embedded Microchips for Detection, Isolation, and Molecular Analysis of Single Circulating Melanoma Cells. *Angewandte Chemie*, **2013**, 125, 3463-3467	3.6	11
25	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. *New England Journal of Medicine*, **2012**, 366, 207-15	59.2	838
24	MDM4 is a key therapeutic target in cutaneous melanoma. *Nature Medicine*, **2012**, 18, 1239-47	50.5	222
23	Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. *Nature Genetics*, **2012**, 44, 1006-14	36.3	887
22	Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. *Nature Communications*, **2012**, 3, 724	17.4	500
21	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. *Nature*, **2012**, 487, 500-4	50.4	1308
20	The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. *Clinical Cancer Research*, **2012**, 18, 2502-14	12.9	130

19	Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. *Cancer Discovery*, **2012**, 2, 414-24	24.4	81
18	Receptor tyrosine kinases in cancer escape from BRAF inhibitors. *Cell Research*, **2012**, 22, 945-7	24.7	20
17	Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. *Molecular Cancer Therapeutics*, **2012**, 11, 2704-8	6.1	68
16	Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. *Molecular Systems Biology*, **2012**, 8, 589	12.2	132
15	Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. *PLoS ONE*, **2011**, 6, e28973	3.7	170
14	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). *Nature*, **2011**, 480, 387-90	50.4	1107
13	Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. *Journal of Translational Medicine*, **2011**, 9, 76	8.5	65
12	Combinatorial treatments that overcome PDGFRB-driven resistance of melanoma cells to V600EB-RAF inhibition. *Cancer Research*, **2011**, 71, 5067-74	10.1	184
11	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. *Nature*, **2010**, 468, 973-7	50.4	1678
10	Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. *Journal of Translational Medicine*, **2010**, 8, 39	8.5	177
9	Transforming growth factor-beta activation promotes genetic context-dependent invasion of immortalized melanocytes. *Cancer Research*, **2008**, 68, 4248-57	10.1	23
8	TGFbeta signaling in growth control, cancer, and heritable disorders. *Cell*, **2000**, 103, 295-309	56.2	2036
7	Multiple modes of repression by the Smad transcriptional corepressor TGIF. *Journal of Biological Chemistry*, **1999**, 274, 37105-10	5.4	140
6	Ubiquitin-dependent degradation of TGF-beta-activated smad2. *Nature Cell Biology*, **1999**, 1, 472-8	23.4	299
5	A Smad transcriptional corepressor. *Cell*, **1999**, 97, 29-39	56.2	473
4	Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. *Nature*, **1997**, 388, 82-7	50.4	310
3	A structural basis for mutational inactivation of the tumour suppressor Smad4. *Nature*, **1997**, 388, 87-93	50.4	382
2	A conserved glutamate is responsible for ion selectivity and pH dependence of the mammalian anion exchangers AE1 and AE2. *Journal of Biological Chemistry*, **1995**, 270, 28751-8	5.4	37

1 Sulfate transport mediated by the mammalian anion exchangers in reconstituted proteoliposomes. *Journal of Biological Chemistry*, **1995**, 270, 11251-6 5.4 26